Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29823561 | 1.00 | SIGMAR1 (0.45) | SIGMAR1KDM4EACKR3SMN1; SMN2CXCR4 | |
| SCHEMBL1877208 | 0.85 | ALDH1A1 (0.43) | SIGMAR1KDM4EACKR3SMN1; SMN2CXCR4 | |
| SCHEMBL29823258 | 0.85 | ALDH1A1 (0.43) | SIGMAR1KDM4EACKR3SMN1; SMN2CXCR4 | |
| SCHEMBL29823986 | 0.79 | MEN1 (0.41) | SIGMAR1KDM4EACKR3CXCR4MEN1 | |
| SCHEMBL1872883 | 0.79 | MEN1 (0.41) | SIGMAR1KDM4EACKR3CXCR4MEN1 | |
| SCHEMBL29823432 | 0.77 | CXCR4 (0.49) | SIGMAR1CXCR4CYP3A4CYP2D6 | |
| SCHEMBL1877188 | 0.77 | CXCR4 (0.49) | SIGMAR1CXCR4CYP3A4CYP2D6 | |
| SCHEMBL22581108 | 0.72 | ALDH1A1 (0.41) | SMN1; SMN2MEN1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL1879911 | 0.71 | ALDH1A1 (0.39) | SIGMAR1KDM4ESMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL29823495 | 0.70 | CCR3 (0.45) | KDM4EMEN1ALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371361-A1 | Methods to mobilize progenitor/stem cells | Genzyme Global S.à.r.l. (LU) | 2011-10-05 | — | — | EP | claimed |
| US-7935692-B2 | Methods to mobilize progenitor/stem cells | GENZYME CORPORATION (US) | 2011-05-03 | — | — | US | claimed |
| US-20100035941-A1 | METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION | GENZYME CORPORATION | 2010-02-11 | — | — | US | claimed |
| US-20060264434-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED INC. (CA) | 2006-11-23 | — | — | US | claimed |
| EP-1163238-B1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2006-05-31 | — | — | EP | claimed |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-11-25 | — | — | US | claimed |
| US-20250295698-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM CELLS | ENSOMA INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250032549-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | ENSOMA INC (US) | 2025-01-30 | — | — | US | disclosed |
| US-20240189387-A1 | DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS | ENSOMA, INC. | 2024-06-13 | — | — | US | disclosed |
| EP-3735412-B1 | COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AND TREATMENT OF INHERITED METABOLIC DISORDERS | EDIGENE BIOTECHNOLOGY INC (CN) | 2024-02-21 | — | — | EP | disclosed |
| EP-4308694-A1 | DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS | Magenta Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20230414565-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES | ENSOMA, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230130646-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM CELLS | Magenta Therapeutics, Inc. (US) | 2023-04-27 | — | — | US | disclosed |
| EP-1163238-B1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2006-05-31 | — | — | EP | disclosed |
| US-20060035829-A1 | Chemokine combinations to mobilize progenitor/stem cells | ANORMED INC. | 2006-02-16 | — | — | US | disclosed |
| US-6987102-B2 | Methods to mobilize progenitor/stem cells | ANORMED, INC. (CA) | 2006-01-17 | — | — | US | disclosed |
| US-20050043367-A1 | Methods to mobilize progenitor/stem cells | ANORMED CORPORATION (CA) | 2005-02-24 | — | — | US | disclosed |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-11-25 | — | — | US | disclosed |
| US-6750348-B1 | PROTECTIVE EFFECTS AGAINST INFECTION BY HIV THROUGH BINDING TO CHEMOKINE RECEPTORS, INCLUDING CXCR4 AND CCR5;N-(2-PYRIDINYLMETHYL)-N'-(2-(PHENYLUREIDO)ETHYL)-N'-(5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-1,4-BENZENEDIMETHANAMINE | ANORMED, INC. (CA) | 2004-06-15 | — | — | US | disclosed |
| US-20030130250-A1 | Methods to mobilize progenitor/stem cells | ANORMED, INC. (CA) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264434-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR4, CXCR1 | SIGMAR1 73/4885KDM4E 4279/4885ACKR3 15/4885 |
| US-20240189387-A1 | DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS | CXCL12, MCL1, MYADM | SIGMAR1 4776/4885KDM4E 2556/4885ACKR3 60/4885 |
| US-20230130646-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM CELLS | CXCL12, CSF3R, THPO | SIGMAR1 4856/4885KDM4E 4210/4885ACKR3 22/4885 |
| US-20050043367-A1 | Methods to mobilize progenitor/stem cells | CXCL12, CXCR4, CXCR1 | SIGMAR1 197/4885KDM4E 2301/4885ACKR3 5/4885 |
| US-20230414565-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES | MCL1, CXCL12, KIT | SIGMAR1 4683/4885KDM4E 3332/4885ACKR3 28/4885 |
| US-20060035829-A1 | Chemokine combinations to mobilize progenitor/stem cells | CXCL12, CXCR2, CXCR4 | SIGMAR1 1845/4885KDM4E 4804/4885ACKR3 11/4885 |
| US-20100035941-A1 | METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION | CCR2, CXCR4, CXCR2 | SIGMAR1 144/4885KDM4E 2151/4885ACKR3 12/4885 |
| US-20250032549-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | CXCL12, CD44, CD47 | SIGMAR1 4862/4885KDM4E 2938/4885ACKR3 47/4885 |
| US-20030130250-A1 | Methods to mobilize progenitor/stem cells | CXCR4, CXCL12, CXCR2 | SIGMAR1 233/4885KDM4E 2485/4885ACKR3 11/4885 |
| US-20250295698-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM CELLS | CXCL12, CSF3R, THPO | SIGMAR1 4856/4885KDM4E 4210/4885ACKR3 22/4885 |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR4, CXCR1 | SIGMAR1 87/4885KDM4E 4473/4885ACKR3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.